Page 1 | Search Results | Blood | American Society of Hematology

1-13 of 13

Sort by

Sort Order Select

Journal Articles

A Phase 2 Study of Dasatinib, Prednisone, and Blinatumomab for Older Patients with Philadelphia-Chromosome (Ph) Positive or Ph-like Acute Lymphoblastic Leukemia (ALL) (with Dasatinib Sensitive Fusions/ Mutations)

Anjali Advani, Anna Moseley, Kristen O'Dwyer, Brent Wood, Jae H Park, Matthew Wieduwilt, Deepa Jeyakumar, George Yaghmour, Ehab L. Atallah, Aaron T. Gerds, Susan M. O'Brien, Jane L. Liesveld, Megan Othus, Mark R. Litzow, Richard M. Stone, Elad Sharon, Harry P. Erba

Blood (2021) 138 (Supplement 1): 3397.

https://doi.org/10.1182/blood-2021-145529

Published: 2021

Journal Articles

A Phase 1a/b Dose Escalation Study of the MYC Repressor Apto-253 in Patients with Relapsed or Refractory AML or High-Risk MDS

Maro Ohanian, Martha L. Arellano, Moshe Y. Levy, Kristen O'Dwyer, Hani Babiker, Daruka Mahadevan, Hongying Zhang, Nasrin Rastgoo, Yuying Jin, Jotin Marango, Stephen B Howell, William G Rice, Rafael Bejar

Blood (2021) 138 (Supplement 1): 3411.

https://doi.org/10.1182/blood-2021-150049

Published: 2021

Journal Articles

Treatment strategies for adolescent and young adult patients with acute myeloid leukemia

Kristen O’Dwyer, David R. Freyer, John T. Horan

Blood (2018) 132 (4): 362–368.

https://doi.org/10.1182/blood-2017-12-778472

Published: 2018

Journal Articles

A Phase 1 Trial of Inotuzumab in Combination with CVP (Cyclophosphamide, Vincristine, Prednisone) for Relapsed/ Refractory CD22+ Acute Leukemia (SWOG 1312)

Anjali S. Advani, MD, Anna Moseley, Michaela Liedtke, MD, Margaret O'Donnell, MD, Megan Othus, PhD, Martha P. Mims, MD PhD, Kristen O'Dwyer, MD, Harry P. Erba, MD PhD

Blood (2016) 128 (22): 1634.

https://doi.org/10.1182/blood.V128.22.1634.1634

Published: 2016

Journal Articles

Importance of Achieving Complete Remission (CR) after Intensive Therapy for Acute Myeloid Leukemia (AML) in Older Adults Age ≥60 Years: Analysis of Risk Factors for Early Mortality and Re-Induction, and Impact of Quality of Response on Overall Survival (OS) in the ECOG-ACRIN E2906 Randomized Trial

Blood (2016) 128 (22): 339.

https://doi.org/10.1182/blood.V128.22.339.339

Published: 2016

Journal Articles

Distinct Properties of Leukemia Stem Cells in Primary Refractory Acute Myeloid Leukemia

Jason H. Mendler, MD PhD, Marlene Balys, Umayal Sivagnanalingam, Allison Eberhardt, Korinne Thorne, Tzu-Chieh Ho, PhD, Mark W. LaMere, BA, Samuel Moore, Helene McMurray, PhD, Jason R. Myers, John M. Ashton, PhD, Kristen O'Dwyer, MD, Jane L. Liesveld, MD, Laura M. Calvi, MD, Michael W. Becker, MD

Blood (2015) 126 (23): 685.

https://doi.org/10.1182/blood.V126.23.685.685

Published: 2015

Journal Articles

A Role for IL1RAP in Acute Myelogenous Leukemia Stem Cells Following Treatment and Progression

Tzu-Chieh Ho, PhD, Craig T Jordan, PhD, Mark W. LaMere, BA, John M. Ashton, PhD, Kristen O'Dwyer, MD, Jason H. Mendler, MD PhD, Jane L. Liesveld, MD, Eunice S. Wang, MD, Monica L. Guzman, PhD, Laura M. Calvi, MD, Michael W. Becker, MD

Blood (2015) 126 (23): 4266.

https://doi.org/10.1182/blood.V126.23.4266.4266

Published: 2015

Journal Articles

North American Leukemia, Intergroup Phase III Randomized Trial of Single Agent Clofarabine As Induction and Post-Remission Therapy, and Decitabine As Maintenance Therapy in Newly-Diagnosed Acute Myeloid Leukemia in Older Adults (Age ≥60 Years): A Trial of the ECOG-ACRIN Cancer Research Group (E2906)

Blood (2015) 126 (23): 217.

https://doi.org/10.1182/blood.V126.23.217.217

Published: 2015

Journal Articles

Report of the Relapsed/Refractory Cohort of SWOG S0919: A Phase 2 Study of Idarubicin and Cytarabine in Combination with Pravastatin for Acute Myelogenous Leukemia

Anjali S. Advani, MD, Hongli Li, PhD, Laura C. Michaelis, MD, Bruno C. Medeiros, MD, Michaela Liedtke, MD, Alan F. List, MD, Kristen O'Dwyer, MD, Megan Othus, PhD, Harry P. Erba, MD PhD, Frederick R Appelbaum, MD

Blood (2015) 126 (23): 3803.

https://doi.org/10.1182/blood.V126.23.3803.3803

Published: 2015

Journal Articles

Clinical and Biologic Effects Of The Angiopoietin 1/2 Neutralizing Peptibody, Trebananib (AMG 386), In Acute Myeloid Leukemia Patients

Eunice S. Wang, MD, Gerald Fetterly, PhD, William Brady, Wei Tan, Jessica Greene, Allison Gaudy, Carlos E Vigil, MD, Jason H. Mendler, MD, PhD, Michael W. Becker, MD, Kristen O'Dwyer, MD, Jane L. Liesveld, MD, Meir Wetzler, MD

Blood (2013) 122 (21): 2701.

https://doi.org/10.1182/blood.V122.21.2701.2701

Published: 2013

Journal Articles

Evolution Of Acute Myelogenous Leukemia Stem Cell Properties Following Treatment and Progression

TzuChieh Ho, BS, Mark W LaMere, BS, Kristen O'Dwyer, MD, Jason H. Mendler, MD, PhD, Jane L. Liesveld, MD, Meir Wetzler, MD, Eunice S. Wang, MD, Monica L. Guzman, PhD, Craig T. Jordan, PhD, Michael W. Becker, MD

Blood (2013) 122 (21): 883.

https://doi.org/10.1182/blood.V122.21.883.883

Published: 2013

Journal Articles

Phase I Study of Decitabine and Rapamycin in Relapsed/Refractory Acute Myelogenous Leukemia

Jane L. Liesveld, MD, Kristen O'Dwyer, MD, Michael W. Becker, MD, Deborah Mulford, MD, Alison Walker, MD, Rui Chen, PhD, Jeremy Bechelli, MS, Karen Rosell, BS, Craig T. Jordan, PhD, Mohammad Minhajuddin, PhD, Gordon L. Phillips, II, MD

Blood (2012) 120 (21): 3549.

https://doi.org/10.1182/blood.V120.21.3549.3549

Published: 2012

Journal Articles

Bcl-2 Inhibitor ABT-263 Targets Oxidative Phosphorylation and Selectively Eradicates Quiescent Human Leukemia Stem Cells

Eleni D Lagadinou, MD/PhD, Alexander Sach, BS, Kevin P Callahan, PhD, Randall M. Rossi, MS, Sarah Neering, MS, Shanshan Pei, BS, Kristen O'Dwyer, MD, Jane L. Liesveld, MD, Paul S. Brookes, PhD, Michael W. Becker, MD, Craig T. Jordan, PhD

Blood (2012) 120 (21): 206.

https://doi.org/10.1182/blood.V120.21.206.206

Published: 2012

NARROW

A Phase 2 Study of Dasatinib, Prednisone, and Blinatumomab for Older Patients with Philadelphia-Chromosome (Ph) Positive or Ph-like Acute Lymphoblastic Leukemia (ALL) (with Dasatinib Sensitive Fusions/ Mutations)

A Phase 1a/b Dose Escalation Study of the MYC Repressor Apto-253 in Patients with Relapsed or Refractory AML or High-Risk MDS

Treatment strategies for adolescent and young adult patients with acute myeloid leukemia

A Phase 1 Trial of Inotuzumab in Combination with CVP (Cyclophosphamide, Vincristine, Prednisone) for Relapsed/ Refractory CD22+ Acute Leukemia (SWOG 1312)

Importance of Achieving Complete Remission (CR) after Intensive Therapy for Acute Myeloid Leukemia (AML) in Older Adults Age ≥60 Years: Analysis of Risk Factors for Early Mortality and Re-Induction, and Impact of Quality of Response on Overall Survival (OS) in the ECOG-ACRIN E2906 Randomized Trial

Distinct Properties of Leukemia Stem Cells in Primary Refractory Acute Myeloid Leukemia

A Role for IL1RAP in Acute Myelogenous Leukemia Stem Cells Following Treatment and Progression

Report of the Relapsed/Refractory Cohort of SWOG S0919: A Phase 2 Study of Idarubicin and Cytarabine in Combination with Pravastatin for Acute Myelogenous Leukemia

Clinical and Biologic Effects Of The Angiopoietin 1/2 Neutralizing Peptibody, Trebananib (AMG 386), In Acute Myeloid Leukemia Patients

Evolution Of Acute Myelogenous Leukemia Stem Cell Properties Following Treatment and Progression

Phase I Study of Decitabine and Rapamycin in Relapsed/Refractory Acute Myelogenous Leukemia

Bcl-2 Inhibitor ABT-263 Targets Oxidative Phosphorylation and Selectively Eradicates Quiescent Human Leukemia Stem Cells

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only